178 related articles for article (PubMed ID: 22747609)
1. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas.
Motomura K; Natsume A; Watanabe R; Ito I; Kato Y; Momota H; Nishikawa R; Mishima K; Nakasu Y; Abe T; Namba H; Nakazato Y; Tashiro H; Takeuchi I; Mori T; Wakabayashi T
Cancer Sci; 2012 Oct; 103(10):1871-9. PubMed ID: 22747609
[TBL] [Abstract][Full Text] [Related]
2. A simplified integrated molecular and immunohistochemistry-based algorithm allows high accuracy prediction of glioblastoma transcriptional subtypes.
Orzan F; Pagani F; Cominelli M; Triggiani L; Calza S; De Bacco F; Medicina D; Balzarini P; Panciani PP; Liserre R; Buglione M; Fontanella MM; Medico E; Galli R; Isella C; Boccaccio C; Poliani PL;
Lab Invest; 2020 Oct; 100(10):1330-1344. PubMed ID: 32404931
[TBL] [Abstract][Full Text] [Related]
3. A simplified approach for the molecular classification of glioblastomas.
Le Mercier M; Hastir D; Moles Lopez X; De Nève N; Maris C; Trepant AL; Rorive S; Decaestecker C; Salmon I
PLoS One; 2012; 7(9):e45475. PubMed ID: 23029035
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma.
Park J; Shim JK; Yoon SJ; Kim SH; Chang JH; Kang SG
Sci Rep; 2019 Jul; 9(1):10555. PubMed ID: 31332251
[TBL] [Abstract][Full Text] [Related]
5. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma.
Zhang JX; Zhang J; Yan W; Wang YY; Han L; Yue X; Liu N; You YP; Jiang T; Pu PY; Kang CS
Neuro Oncol; 2013 Mar; 15(3):279-89. PubMed ID: 23295773
[TBL] [Abstract][Full Text] [Related]
6. Proteogenomics of glioblastoma associates molecular patterns with survival.
Yanovich-Arad G; Ofek P; Yeini E; Mardamshina M; Danilevsky A; Shomron N; Grossman R; Satchi-Fainaro R; Geiger T
Cell Rep; 2021 Mar; 34(9):108787. PubMed ID: 33657365
[TBL] [Abstract][Full Text] [Related]
7. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
[TBL] [Abstract][Full Text] [Related]
8. Molecular Subgroups of Glioblastoma- an Assessment by Immunohistochemical Markers.
Nagy Á; Garzuly F; Padányi G; Szűcs I; Feldmann Á; Murnyák B; Hortobágyi T; Kálmán B
Pathol Oncol Res; 2019 Jan; 25(1):21-31. PubMed ID: 28948518
[TBL] [Abstract][Full Text] [Related]
9. Molecular heterogeneity of glioblastomas: does location matter?
Denicolaï E; Tabouret E; Colin C; Metellus P; Nanni I; Boucard C; Tchoghandjian A; Meyronet D; Baeza-Kallee N; Chinot O; Figarella-Branger D
Oncotarget; 2016 Jan; 7(1):902-13. PubMed ID: 26637806
[TBL] [Abstract][Full Text] [Related]
10. Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification.
Li B; Senbabaoglu Y; Peng W; Yang ML; Xu J; Li JZ
Clin Cancer Res; 2012 Oct; 18(20):5595-605. PubMed ID: 22912392
[TBL] [Abstract][Full Text] [Related]
11. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
[TBL] [Abstract][Full Text] [Related]
13. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Verhaak RG; Hoadley KA; Purdom E; Wang V; Qi Y; Wilkerson MD; Miller CR; Ding L; Golub T; Mesirov JP; Alexe G; Lawrence M; O'Kelly M; Tamayo P; Weir BA; Gabriel S; Winckler W; Gupta S; Jakkula L; Feiler HS; Hodgson JG; James CD; Sarkaria JN; Brennan C; Kahn A; Spellman PT; Wilson RK; Speed TP; Gray JW; Meyerson M; Getz G; Perou CM; Hayes DN;
Cancer Cell; 2010 Jan; 17(1):98-110. PubMed ID: 20129251
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
Brown KE; Chagoya G; Kwatra SG; Yen T; Keir ST; Cooter M; Hoadley KA; Rasheed A; Lipp ES; Mclendon R; Ali-Osman F; Bigner DD; Sampson JH; Kwatra MM
J Neurochem; 2015 Jun; 133(5):730-8. PubMed ID: 25598002
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
Carrato C; Alameda F; Esteve-Codina A; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Lopez-Martos R; Barco SD; Ribalta T; Capellades J; Puig J; Gallego O; Mesia C; Muñoz-Marmol AM; Archilla I; Arumí M; Blanc JM; Bellosillo B; Menendez S; Esteve A; Bagué S; Hernandez A; Craven-Bartle J; Fuentes R; Vidal N; Aldecoa I; Iglesia N; Balana C
Clin Cancer Res; 2020 Dec; 26(24):6600-6609. PubMed ID: 32998960
[TBL] [Abstract][Full Text] [Related]
16. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.
Gill BJ; Pisapia DJ; Malone HR; Goldstein H; Lei L; Sonabend A; Yun J; Samanamud J; Sims JS; Banu M; Dovas A; Teich AF; Sheth SA; McKhann GM; Sisti MB; Bruce JN; Sims PA; Canoll P
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12550-5. PubMed ID: 25114226
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.
Brennan C; Momota H; Hambardzumyan D; Ozawa T; Tandon A; Pedraza A; Holland E
PLoS One; 2009 Nov; 4(11):e7752. PubMed ID: 19915670
[TBL] [Abstract][Full Text] [Related]
18. CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.
Zhao H; Zhou X; Yuan G; Hou Z; Sun H; Zhai N; Huang B; Li X
Clin Transl Oncol; 2021 Mar; 23(3):565-571. PubMed ID: 32661826
[TBL] [Abstract][Full Text] [Related]
19. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
20. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
